Literature DB >> 1752704

Immunomodulatory action of levamisole--I. Structural analysis and immunomodulating activity of levamisole degradation products.

K A Hanson1, D L Nagel, M L Heidrick.   

Abstract

In our laboratory we observed that solutions of levamisole (LMS) stored at 4 degrees C consistently enhanced the lymphocyte proliferation response to concanavalin A (Con A) more than freshly prepared solutions did. To determine if the increased immunopotentiation observed with the stored solutions of LMS was due to products formed from LMS, we assessed the stability of LMS when stored at 4 or 37 degrees C at pH 6, 7, 7.5 and 8. Analysis of the various solutions by high pressure liquid chromatography demonstrated that LMS decomposes during storage in neutral and alkaline conditions to form three products. The formation of the products was accelerated by increasing the temperature from 4 to 37 degrees C. The three degradation products were purified by preparative high pressure liquid chromatography and their structures determined by mass spectrometry, infrared spectrometry and homo- and heteronuclear two dimensional nuclear magnetic resonance spectroscopy. The degradation products, denoted as No. 1, No. 2 and No. 3, based on their high pressure liquid chromatography retention times, were identified as: No. 1, 3-(2-mercaptoethyl)-5-phenylimidazolidine-2-one; No. 2, 6-phenyl-2,3-dihydroimidazo (2,1-b) thiazole and No. 3, bis [3-(2-oxo-5-phenylimidazolidin-1-yl) ethyl] disulfide. Product 2 significantly enhanced murine lymphocyte proliferation responses to concanavalin A (Con A) at concentrations between 0.5 and 10.0 micrograms/ml (whereas the optimum concentration of LMS is 10-100 fold higher (50-100 micrograms/ml)). Products 1, 2 and 3 significantly inhibited the lymphocyte proliferative response at concentrations greater than 2.2, 10.0 and 10.0 micrograms/ml, respectively. These studies indicate that under relatively mild conditions, including physiological conditions, LMS may decompose to products which inhibit or enhance lymphocyte responses to Con A.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752704     DOI: 10.1016/0192-0561(91)90178-a

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  3 in total

1.  The immunomodulatory effect of levamisole is influenced by postoperative changes and type of lymphocyte stimulant.

Authors:  E E Abdalla; I J Adam; G E Blair; A Boylston; H M Sue-Ling; P Finan; D Johnston
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

2.  2-[6-(4-Chloro-phen-yl)imidazo[2,1-b][1,3]thia-zol-2-yl]-N'-[(E)-4-meth-oxy-benzyl-idene]acetohydrazide.

Authors:  Mehmet Akkurt; Nuray Ulusoy Güzeldemirci; Berin Karaman; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-12-18

3.  Can levamisole upregulate the equine cell-mediated macrophage (M1) dendritic cell (DC1) T-helper 1 (CD4 Th1) T-cytotoxic (CD8) immune response in vitro?

Authors:  Sharon Witonsky; Virginia Buechner-Maxwell; Amy Santonastasto; Robert Pleasant; Stephen Werre; Bettina Wagner; Siobhan Ellison; David Lindsay
Journal:  J Vet Intern Med       Date:  2019-01-29       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.